Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
PHASE2CompletedINTERVENTIONAL
Enrollment
33
Participants
Timeline
Start Date
February 7, 2018
Primary Completion Date
December 30, 2021
Study Completion Date
March 24, 2022
Conditions
Biliary Tract Cancer
Interventions
DRUG
MK3475
anti-PD1 immunotherapy
Trial Locations (1)
06351
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT03110328 - Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes | Biotech Hunter | Biotech Hunter